دورية أكاديمية
أعرض في EDS

T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment.

التفاصيل البيبلوغرافية
العنوان: T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment.
المؤلفون: Wearn AR; Bristol Medical School, University of Bristol, Bristol, UK. Alfie.wearn@bristol.ac.uk.; Institute of Clinical Neurosciences, North Bristol NHS Trust, Bristol, UK. Alfie.wearn@bristol.ac.uk., Nurdal V; Bristol Medical School, University of Bristol, Bristol, UK., Saunders-Jennings E; Bristol Medical School, University of Bristol, Bristol, UK., Knight MJ; School of Psychological Science, University of Bristol, Bristol, UK., Isotalus HK; Bristol Medical School, University of Bristol, Bristol, UK., Dillon S; Bristol Medical School, University of Bristol, Bristol, UK., Tsivos D; Bristol Medical School, University of Bristol, Bristol, UK., Kauppinen RA; School of Psychological Science, University of Bristol, Bristol, UK., Coulthard EJ; Bristol Medical School, University of Bristol, Bristol, UK.; Institute of Clinical Neurosciences, North Bristol NHS Trust, Bristol, UK.
المصدر: Alzheimer's research & therapy [Alzheimers Res Ther] 2020 Sep 10; Vol. 12 (1), pp. 105. Date of Electronic Publication: 2020 Sep 10.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central Ltd.
مواضيع طبية MeSH: Alzheimer Disease*/complications , Alzheimer Disease*/diagnostic imaging , Cognitive Dysfunction*/diagnostic imaging, Atrophy ; Biomarkers ; Cohort Studies ; Humans ; Magnetic Resonance Imaging
مستخلص: Background: Early Alzheimer's disease (AD) diagnosis is vital for development of disease-modifying therapies. Prior to significant brain tissue atrophy, several microstructural changes take place as a result of Alzheimer's pathology. These include deposition of amyloid, tau and iron, as well as altered water homeostasis in tissue and some cell death. T2 relaxation time, a quantitative MRI measure, is sensitive to these changes and may be a useful non-invasive, early marker of tissue integrity which could predict conversion to dementia. We propose that different microstructural changes affect T2 in opposing ways, such that average 'midpoint' measures of T2 are less sensitive than measuring distribution width (heterogeneity). T2 heterogeneity in the brain may present a sensitive early marker of AD pathology.
Methods: In this cohort study, we tested 97 healthy older controls, 49 people with mild cognitive impairment (MCI) and 10 with a clinical diagnosis of AD. All participants underwent structural MRI including a multi-echo sequence for quantitative T2 assessment. Cognitive change over 1 year was assessed in 20 participants with MCI. T2 distributions were modelled in the hippocampus and thalamus using log-logistic distribution giving measures of log-median value (midpoint; T2μ) and distribution width (heterogeneity; T2σ).
Results: We show an increase in T2 heterogeneity (T2σ; p < .0001) in MCI compared to healthy controls, which was not seen with midpoint (T2μ; p = .149) in the hippocampus and thalamus. Hippocampal T2 heterogeneity predicted cognitive decline over 1 year in MCI participants (p = .018), but midpoint (p = .132) and volume (p = .315) did not. Age affects T2, but the effects described here are significant even after correcting for age.
Conclusions: We show that T2 heterogeneity can identify subtle changes in microstructural integrity of brain tissue in MCI and predict cognitive decline over a year. We describe a new model that considers the competing effects of factors that both increase and decrease T2. These two opposing forces suggest that previous conclusions based on T2 midpoint may have obscured the true potential of T2 as a marker of subtle neuropathology. We propose that T2 heterogeneity reflects microstructural integrity with potential to be a widely used early biomarker of conditions such as AD.
References: Neurochem Res. 2005 Feb;30(2):201-5. (PMID: 15895823)
Alzheimers Dement. 2011 May;7(3):270-9. (PMID: 21514249)
J Magn Reson Imaging. 2019 Feb;49(2):445-455. (PMID: 30209854)
J Neurochem. 2000 Jan;74(1):270-9. (PMID: 10617129)
J Alzheimers Dis. 2011;23(2):221-37. (PMID: 20966552)
Neurobiol Dis. 2006 Apr;22(1):199-208. (PMID: 16337798)
Clin Geriatr Med. 2013 Nov;29(4):753-72. (PMID: 24094295)
Neuropsychologia. 2004;42(10):1394-413. (PMID: 15193947)
Alzheimers Dement. 2018 Aug;14(8):998-1004. (PMID: 29679574)
Lancet Neurol. 2006 Mar;5(3):228-34. (PMID: 16488378)
Magn Reson Med. 2015 Jan;73(1):70-81. (PMID: 24604728)
Br J Psychiatry. 1992 Feb;160:187-90. (PMID: 1540758)
Med Clin North Am. 2013 May;97(3):399-424. (PMID: 23642578)
Acta Neuropathol. 1991;82(4):239-59. (PMID: 1759558)
Neurobiol Aging. 2004 Aug;25(7):843-51. (PMID: 15212838)
Hum Brain Mapp. 2015 Jan;36(1):258-87. (PMID: 25181316)
Biofactors. 2012 Mar-Apr;38(2):133-8. (PMID: 22447715)
Neurology. 2009 Mar 17;72(11):999-1007. (PMID: 19289740)
Front Cell Neurosci. 2018 Dec 18;12:488. (PMID: 30618635)
EMBO Mol Med. 2016 Jun 01;8(6):595-608. (PMID: 27025652)
Neurobiol Aging. 2011 Aug;32(8):1341-71. (PMID: 19775776)
Phys Med Biol. 2016 Aug 7;61(15):5587-605. (PMID: 27384985)
Neurosci Lett. 2004 Jun 10;363(2):150-3. (PMID: 15172104)
Neuroimage. 2015 Jul 15;115:117-37. (PMID: 25936807)
Int J Epidemiol. 2002 Apr;31(2):285-93. (PMID: 11980781)
J Alzheimers Dis. 2013;37(1):127-36. (PMID: 23792695)
Neurology. 2003 Jan 28;60(2):253-60. (PMID: 12552040)
Brain. 2008 Mar;131(Pt 3):665-80. (PMID: 18263627)
Neuroscience. 2015 Nov 19;309:29-50. (PMID: 26306871)
IEEE Trans Med Imaging. 2001 Jan;20(1):45-57. (PMID: 11293691)
Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84. (PMID: 7566337)
Neurology. 2000 Aug 22;55(4):484-89. (PMID: 10953178)
Alzheimers Res Ther. 2014 Jul 03;6(4):37. (PMID: 25024750)
Trends Neurosci. 1997 Nov;20(11):517-23. (PMID: 9364666)
Magn Reson Med. 2008 Jul;60(1):41-52. (PMID: 18523986)
Brain. 2008 Dec;131(Pt 12):3266-76. (PMID: 18988639)
Hum Brain Mapp. 2002 Nov;17(3):143-55. (PMID: 12391568)
Arch Neurol. 2009 Dec;66(12):1447-55. (PMID: 20008648)
PLoS One. 2013 Sep 30;8(9):e76203. (PMID: 24098779)
Brain Res Bull. 2001 Feb;54(3):255-66. (PMID: 11287130)
Neurosci Lett. 1992 Jan 6;134(2):187-90. (PMID: 1589144)
NMR Biomed. 2007 May;20(3):343-51. (PMID: 17451178)
Top Magn Reson Imaging. 2006 Feb;17(1):19-30. (PMID: 17179894)
J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019)
Neurology. 1999 Apr 22;52(7):1397-403. (PMID: 10227624)
Acta Psychiatr Scand. 2009 Apr;119(4):252-65. (PMID: 19236314)
Arch Gen Psychiatry. 2006 Jan;63(1):63-72. (PMID: 16389198)
Brain Res Bull. 2018 Jun;140:176-189. (PMID: 29738781)
Lancet Neurol. 2014 Oct;13(10):1045-60. (PMID: 25231526)
Alzheimers Dement. 2015 Mar;11(3):332-84. (PMID: 25984581)
NMR Biomed. 2015 Mar;28(3):297-305. (PMID: 25530083)
J Huazhong Univ Sci Technolog Med Sci. 2011 Aug;31(4):578. (PMID: 21823025)
Magn Reson Med. 2004 Apr;51(4):794-8. (PMID: 15065253)
J Neurol Sci. 2007 Jun 15;257(1-2):97-104. (PMID: 17316690)
Curr Alzheimer Res. 2016;13(5):534-44. (PMID: 26567737)
Neurology. 2007 Jan 23;68(4):288-91. (PMID: 17242334)
J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1235-44. (PMID: 15314108)
Neurobiol Aging. 2002 Nov-Dec;23(6):1089-92. (PMID: 12470807)
J Neuropathol Exp Neurol. 1999 Apr;58(4):376-88. (PMID: 10218633)
AJNR Am J Neuroradiol. 2006 Feb;27(2):430-9. (PMID: 16484425)
Neurology. 2006 Jan 24;66(2):236-8. (PMID: 16434661)
Arch Neurol. 1993 Sep;50(9):967-73. (PMID: 8363451)
Radiology. 1997 Oct;205(1):197-201. (PMID: 9314985)
Acta Neuropathol Commun. 2014 Sep 18;2:135. (PMID: 25231068)
Neurology. 2004 Feb 24;62(4):591-600. (PMID: 14981176)
Biomed Spectrosc Imaging. 2017 Jun 20;6(1-2):25-35. (PMID: 28685128)
Neurobiol Aging. 2014 Jul;35(7):1549-61. (PMID: 24582637)
Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250)
Neurobiol Aging. 1996 Jul-Aug;17(4):535-40. (PMID: 8832627)
Neurology. 1992 Sep;42(9):1681-8. (PMID: 1307688)
J Neural Transm (Vienna). 1996;103(4):455-90. (PMID: 9617789)
Magn Reson Med. 1988 Mar;6(3):265-74. (PMID: 3362061)
J Alzheimers Dis. 2010;19(1):363-72. (PMID: 20061651)
Neurology. 2002 Jun 25;58(12):1791-800. (PMID: 12084879)
J Magn Reson Imaging. 2005 Feb;21(2):118-27. (PMID: 15666406)
Neurology. 1999 May 12;52(8):1687-9. (PMID: 10331700)
Biol Psychiatry. 1994 Apr 1;35(7):480-7. (PMID: 8018799)
Neurology. 2008 Jan 15;70(3):191-9. (PMID: 18195264)
معلومات مُعتمدة: 109067/Z/15/AI United Kingdom WT_ Wellcome Trust
فهرسة مساهمة: Keywords: Ageing; Alzheimer’s disease; Early diagnosis; Hippocampus; Magnetic resonance imaging; T2 relaxometry
المشرفين على المادة: 0 (Biomarkers)
تواريخ الأحداث: Date Created: 20200911 Date Completed: 20210624 Latest Revision: 20231112
رمز التحديث: 20231112
مُعرف محوري في PubMed: PMC7488446
DOI: 10.1186/s13195-020-00672-9
PMID: 32912337
قاعدة البيانات: MEDLINE
الوصف
تدمد:1758-9193
DOI:10.1186/s13195-020-00672-9